Tazomeline

Tazomeline

SCHEMBL7615741

CCCCCCSc1nsnc1C1=CCCN(C)C1.O=C(O)C(=O)O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Tazomeline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
CHRM1 P11229 9/20 0.79
CHRM4 P08173 3/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL7642910 1.00 CHRM1 (0.79) CHRM1CHRM4
Oxalic Acid SCHEMBL7619270 1.00 CHRM1 (0.79) CHRM1CHRM4
Oxalic Acid SCHEMBL7614723 0.99 CHRM1 (0.79) CHRM1CHRM4
Oxalic Acid SCHEMBL7611050 0.96 CHRM1 (0.77) CHRM1CHRM4
SCHEMBL6911698 0.94 CHRM1 (0.91) CHRM1CHRM4
Tazomeline SCHEMBL195235 0.94 CHRM1 (0.91) CHRM1CHRM4
SCHEMBL6915120 0.94 CHRM1 (0.91) CHRM1CHRM4
SCHEMBL6912246 0.92 CHRM1 (0.90) CHRM1CHRM4
Oxalic Acid SCHEMBL7616498 0.92 CHRM1 (0.79) CHRM1CHRM4
Oxalic Acid SCHEMBL7619712 0.92 CHRM1 (0.79) CHRM1CHRM4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0734259-B1 Use of piperidine compounds in the treatment of schizophrenia NOVO NORDISK AS (DK) 2002-06-12 EP disclosed
US-5773452-A ALZHEIMER'S DISEASE; COGNITION ACTIVATORS NOVO NORDISK ALS (DK) 1998-06-30 US disclosed
US-5753683-A SCHIZOPHRENIA NOVO NORDISK A/S (DK) 1998-05-19 US disclosed
US-5750541-A 3-(1,2,5-THIA OR OXADIAZOL-3-YL)-1,2,5,6-PYRIDINE DERIVATIVES; SCHIZOPHRENIFORM DISEASES; SIDE EFFECT REDUCTION NOVO NORDISK A/S (DK) 1998-05-12 US disclosed
US-5744489-A ADMINISTERING CERTAIN 1,2,5-THIADIAZOLE AND 1,2,5-OXADIAZOLE COMPOUNDS GREENWOOD BEVERLEY (US) 1998-04-28 US disclosed
US-5712297-A COGNITION ACTIVATORS; ALZHEIMER*S DISEASE NOVO NORDISK A/S (DK) 1998-01-27 US disclosed
EP-0788357-A1 A METHOD OF TREATING URINARY BLADDER DYSFUNCTIONS NOVO NORDISK A/S (DK) 1997-08-13 EP disclosed
US-5565475-A Method of treating urinary bladder dysfunctions with 3-tetrahydropyridine derivatives MUHLHAUSER MARK A (US) 1996-10-15 US disclosed
EP-0734259-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1996-10-02 EP disclosed
US-5559138-A Method of Treating Glaucoma Using Oxadiazolyl or Thiadiazolyl Tetrahydropyridines NOVO NORDISK A/S (DK) 1996-09-24 US disclosed
EP-0687265-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1995-12-20 EP disclosed
EP-0384288-B1 Piperidine compounds and their preparation and use NOVO NORDISK AS (DK) 1995-05-24 EP disclosed
WO-1995005174-A1 ANTIPSYCHOTIC METHOD NOVO NORDISK A/S (DK) 1995-02-23 WO disclosed
WO-1994020495-A1 HETEROCYCLIC COMPOUNDS AND THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1994-09-15 WO disclosed
US-5328925-A Alzheimer*s disease NOVO NORDISK A/S (DK) 1994-07-12 US disclosed
US-5284859-A Analgesics, Alzheimer's disease NOVO NORDISK A/S (DK) 1994-02-08 US disclosed
US-5264444-A Cognition activators NOVO NORDISK A/S (DK) 1993-11-23 US disclosed
US-5260311-A Cognition activators, analgesics for sever pain, glaucoma treatment NOVO NORDISK A/S (DK) 1993-11-09 US disclosed
US-5041455-A Stimulants of cognitive function in mammals NOVO NORDISK A/S (DK) 1991-08-20 US disclosed
EP-0384288-A2 Piperidine compounds and their preparation and use NOVO NORDISK A/S (DK) 1990-08-29 EP disclosed